Fax No: 91 (22) 2678 4391 / 5198

Tel. No.: 91 (22) 66888333

Website: http://www.unichemlabs.com CIN: L99999MH1962PLC012451.

Registered & Corporate Office: Unichem Bhavan, Prabhat Estate, S. V. Road, Jogeshwari (West), Mumbai-400102, INDIA.

July 25, 2017

Ref: Stock-exchage/2017-18

Department of Corporate Services Bombay Stock Exchange Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Mr. Hari K
Asst. Vice President – Operations
National Stock Exchange of India Ltd
Exchange Plaza, Bandra – Kurla Complex
Bandra (East), Mumbai – 400 051

Dear Sir,

Ref: BSE Scrip Code -506690: NSE Symbol - UNICHEMLAB

Sub: Disclosures under Reg. 30 of SEBI (Listing Obligations & Disclosure Requirements)

Regulations, 2015.

Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed herewith the press release pertaining to receipt of ANDA approval from United States Food and Drug Administration (USFDA) for Losartan Potassium and Hydrochlorothiazide tablets USP, 50mg/12.5 mg, 100mg/12.5mg, and 100 mg/25mg, which are therapeutically equivalent to Hyzaar Tablets 50mg/12.5 mg, 100mg/12.5mg, and 100 mg/25mg of Merck Sharp & Dohme Corporation.

Please take this on record.

Thank you,

Yours Faithfully,

U. W. W

For UNICHEM LABORATORIES LIMITED

**NEEMA THAKORE** 

Head – Legal & Company Secretary

B:\02 SECRETARIAL\Press Release\20170308\stockex.doc



## **UNICHEM LABORATORIES LIMITED**

Unichem Bhavan Prabhat Estate, Off S.V.Road, Jogeshwari (West), Mumbai - 400 102. Tel. No: +91 (22) 66 888 333 Fex. No: +91 (22) 267 843 91/ 5198 CIN: L99999MH1962PLC012451

## PRESS RELEASE

Mumbai, Tuesday July 25, 2017

<u>Unichem Laboratories receives ANDA approval from USFDA for Losartan Potassium And Hydrochlorothiazide tablets USP</u>

Unichem Laboratories Limited is pleased to announce that it has received ANDA approval from the United States Food and Drug Administration (USFDA) for Losartan Potassium and Hydrochlorothiazide tablets USP, 50mg/12.5 mg, 100mg/12.5mg, and 100 mg/25mg, which are therapeutically equivalent to Hyzaar Tablets 50mg/12.5 mg, 100mg/12.5mg, and 100 mg/25mg of Merck Sharp & Dohme Corporation.

Losartan Potassium and Hydrochlorothiazide is a combination of Losartan Potassium, an angiotensin II receptor blocker (ARB) and Hydrochlorothiazide, a diuretic indicated for treatment of hypertension (to lower blood pressure) and for reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.

The product will be commercialized from Unichem's Ghaziabad plant. Active Pharmaceutical Ingredient will also be made in house at Pithampur/Roha API Plant(s).

## About Unichem Laboratories Limited

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche therapy areas of cardiology, neurology, orthopedics and anti-infectives. The company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms. More information about the company can be found at <a href="https://www.unichemlabs.com">www.unichemlabs.com</a>

## For more information please contact:

Ms. Neema Thakore Ph: +91-22-66888 404

E-mail: neema.thakore@unichemlabs.com

Mr. Rakesh Parikh Ph: +91-22-66888 414

E-mail: rparikh@unichemlabs.com

Disclaimer: This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.